Akwaa et al described an R package for personalized pathway-based classification modeling using metabolomics data. The package contains four main components for compound name mapping, converting from metabolite profiles to pathway profiles, identification of significant pathway features, and classification/prediction. This is a comprehensive pipeline built upon many other R packages.
1) Lack of novel contribution.
It is clear from the manuscript that a key contribution of the package is to use the 'pathifier' package to convert from metabolite concentration profiles to pathway profiles based on PDS scores. The authors have shown how such approach was able to obtain novel insights compared to other approaches. However, a) The algorithm is not a novel contribution, as the pathifier is already published package. b) In terms of novel application (or novel biological insights), the authors' group already demonstrated this in their 2016 Genome Medicine paper "Novel personalized pathway-based metabolomics models reveal key metabolic pathways for breast cancer diagnosis".
2) Lack of user friendliness. a) Users need to know R in order to use this package. However, for researchers familiar with R, they can almost do all these tasks without using this pipeline, as almost all its component packages are already available. Such a pipeline should ideally be implemented to have graphical user interface (GUI) so other people (who don't know R) can still use. b) Even as an R package, the standard publication route is CRAN, with built-in unit testing and vignette tutorial. Installing R package from CRAN is very straightforward as compared to GitHub. In addition, publishing on CRAN also facilitates quality assurance and long-term maintenance.
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